Opendata, web and dolomites

ADJUV-ANT VACCINES SIGNED

Elucidating the Molecular Mechanisms of Synthetic Saponin Adjuvants and Development of Novel Self-Adjuvanting Vaccines

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ADJUV-ANT VACCINES project word cloud

Explore the words cloud of the ADJUV-ANT VACCINES project. It provides you a very rough idea of what is the project "ADJUV-ANT VACCINES" about.

adjuvanting    adjuvant    insights    carbohydrate    strategies    clinic    dimensional    mount    prospective    biology    molecular    transformative    biological    independent    potent    self    ground    unresolved    despite    constructs    structure    arena    helps    vaccines    structural    questions    cancer    immunological    combining    substance    extensive    translation    adjuvants    frontier    synthesis    glycopeptide    induce    trials    gaps    fight    body    mechanisms    antiviral    antitumor    vaccine    explore    connecting    really    breaking    basis    me    deeply    anticancer    extraordinary    cellular    antigens    singularity    clinical    efficacy    mechanistic    weak    group    human    precision    immune    evaluations    gain    chemistry    integration    few    ultimate    multidisciplinary    stimulate    stems    double    approved    toxic    clear    conformational    public    immunology    intensive    underlying    first    identification    critical    chemical    sufficiently    synthetic    probe    context   

Project "ADJUV-ANT VACCINES" data sheet

The following table provides information about the project.

Coordinator
ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS 

Organization address
address: PARQUE TECNOLOGICO EDIFICIO 801 A
city: DERIO VIZCAYA
postcode: 48160
website: www.cicbiogune.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.cicbiogune.es/people/afernandeztejada
 Total cost 1˙499˙218 €
 EC max contribution 1˙499˙218 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-STG
 Funding Scheme ERC-STG
 Starting year 2017
 Duration (year-month-day) from 2017-03-01   to  2022-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS ES (DERIO VIZCAYA) coordinator 1˙499˙218.00

Map

 Project objective

The clinical success of anticancer and antiviral vaccines often requires the use of an adjuvant, a substance that helps stimulate the body’s immune response to the vaccine, making it work better. However, few adjuvants are sufficiently potent and non-toxic for clinical use; moreover, it is not really known how they work. Current vaccine approaches based on weak carbohydrate and glycopeptide antigens are not being particularly effective to induce the human immune system to mount an effective fight against cancer. Despite intensive research and several clinical trials, no such carbohydrate-based antitumor vaccine has yet been approved for public use. In this context, the proposed project has a double, ultimate goal based on applying chemistry to address the above clear gaps in the adjuvant-vaccine field. First, I will develop new improved adjuvants and novel chemical strategies towards more effective, self-adjuvanting synthetic vaccines. Second, I will probe deeply into the molecular mechanisms of the synthetic constructs by combining extensive immunological evaluations with molecular target identification and detailed conformational studies. Thus, the singularity of this multidisciplinary proposal stems from the integration of its main objectives and approaches connecting chemical synthesis and chemical/structural biology with cellular and molecular immunology. This ground-breaking project at the chemistry-biology frontier will allow me to establish my own independent research group and explore key unresolved mechanistic questions in the adjuvant/vaccine arena with extraordinary chemical precision. Therefore, with this transformative and timely research program I aim to (a) develop novel synthetic antitumor and antiviral vaccines with improved properties and efficacy for their prospective translation into the clinic and (b) gain new critical insights into the molecular basis and three-dimensional structure underlying the biological activity of these constructs.

 Publications

year authors and title journal last update
List of publications.
2020 Mattia Ghirardello, Ane Ruiz-de-Angulo, Nagore Sacristan, Diego Barriales, Jesús Jiménez-Barbero, Ana Poveda, Francisco Corzana, Juan Anguita, Alberto Fernández-Tejada
Exploiting structure–activity relationships of QS-21 in the design and synthesis of streamlined saponin vaccine adjuvants
published pages: 719-722, ISSN: 1359-7345, DOI: 10.1039/c9cc07781b
Chemical Communications 56/5 2020-02-12

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ADJUV-ANT VACCINES" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ADJUV-ANT VACCINES" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

CHIPTRANSFORM (2018)

On-chip optical communication with transformation optics

Read More  

OAlipotherapy (2018)

Long-retention liposomic drug-delivery for intra-articular osteoarthritis therapy

Read More  

CohoSing (2019)

Cohomology and Singularities

Read More